​

Blueprint Medicines (BPMC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BPMC Stock Forecast

Blueprint Medicines stock forecast is as follows: an average price target of $122.60 (represents a 36.01% upside from BPMC’s last price of $90.14) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.

BPMC Price Target

The average price target for Blueprint Medicines (BPMC) is $122.60 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $155.00 to $88.00. This represents a potential 36.01% upside from BPMC's last price of $90.14.

BPMC Analyst Ratings

Buy

According to 14 Wall Street analysts, Blueprint Medicines's rating consensus is 'Buy'. The analyst rating breakdown for BPMC stock is 0 'Strong Buy' (0.00%), 9 'Buy' (64.29%), 5 'Hold' (35.71%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Blueprint Medicines Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Ami FadiaNeedham$135.00$89.2451.28%49.77%
Oct 24, 2024David DaiUBS$88.00$84.404.27%-2.37%
Sep 19, 2024Bradley CaninoStifel Nicolaus$155.00$90.9470.44%71.95%
Aug 01, 2024Matthew BieglerOppenheimer$130.00$102.0527.39%44.22%
Jul 29, 2024Peter LawsonBarclays$105.00$112.19-6.41%16.49%
Jul 08, 2024Matthew BieglerOppenheimer$125.00$116.557.25%38.67%
May 06, 2024Andrew BerensLeerink Partners$97.00$107.19-9.51%7.61%
May 03, 2024Christopher RaymondRaymond James$104.00$106.28-2.15%15.38%
May 03, 2024Andrew FeinH.C. Wainwright$135.00$107.0026.17%49.77%
Dec 14, 2022Needham$60.00$46.6028.76%-33.44%
Nov 02, 2022Andrew FeinH.C. Wainwright$70.00$46.1051.84%-22.34%
Sep 06, 2022Matthew BieglerOppenheimer$90.00$70.6627.37%-0.16%
Aug 17, 2022Derek ArchilaWells Fargo$41.00$52.77-22.31%-54.52%
May 18, 2022Christopher RaymondPiper Sandler$65.00$55.5017.12%-27.89%
Feb 01, 2022Michael UlzMorgan Stanley$92.00$79.1616.22%2.06%
Jan 03, 2022Michael SchmidtGuggenheim$122.00$110.0810.83%35.35%
Nov 09, 2021Dane LeoneRaymond James$133.00$114.9515.70%47.55%
Jul 29, 2021Salveen RichterGoldman Sachs$147.00$84.7473.47%63.08%
Jun 17, 2021Arlinda LeeCanaccord Genuity$120.00$83.5343.66%33.13%

The latest Blueprint Medicines stock forecast, released on Oct 31, 2024 by Ami Fadia from Needham, set a price target of $135.00, which represents a 51.28% increase from the stock price at the time of the forecast ($89.24), and a 49.77% increase from BPMC last price ($90.14).

Blueprint Medicines Price Target by Period

1M3M12M
# Anlaysts-39
Avg Price Target-$126.00$119.33
Last Closing Price$90.14$90.14$90.14
Upside/Downside-100.00%39.78%32.38%

In the current month, the average price target of Blueprint Medicines stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Blueprint Medicines's last price of $90.14. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024CitigroupBuyBuyHold
Oct 31, 2024NeedhamBuyBuyHold
Oct 30, 2024OppenheimerOutperformOutperformHold
Oct 24, 2024UBSBuyBuyHold
Oct 24, 2024UBSNeutralInitialise
Aug 01, 2024OppenheimerOutperformOutperformHold
Jul 29, 2024StephensBuyBuyHold
Jul 29, 2024BarclaysEqual-WeightEqual-WeightHold
Jul 12, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jul 07, 2024OppenheimerOutperformOutperformHold
Jun 28, 2024WedbushMarket OutperformMarket OutperformHold
Jun 28, 2024StephensUnderperformUnderperformHold
Jun 07, 2024StephensUnderperformUnderperformHold
Jun 07, 2024WedbushMarket OutperformMarket OutperformHold
May 14, 2024StephensUnderperformUnderperformHold
May 14, 2024WedbushMarket PerformMarket PerformHold
May 13, 2024StephensOverweightInitialise
May 06, 2024Leerink PartnersMarket PerformUpgrade
May 03, 2024Piper SandlerNeutralNeutralHold
May 03, 2024H.C. WainwrightBuyBuyHold
May 03, 2024BarclaysEqual-WeightEqual-WeightHold
May 02, 2024OppenheimerOutperformOutperformHold
Feb 13, 2024Wells FargoMarket OutperformMarket OutperformHold
Feb 13, 2024Raymond JamesUnderperformUnderperformHold
Jan 09, 2024Wells FargoBuyBuyHold
Dec 22, 2023Raymond JamesStrong BuyStrong BuyHold
Oct 27, 2023BarclaysEqual-WeightEqual-WeightHold
Oct 27, 2023NeedhamBuyBuyHold
Jul 31, 2023Wells FargoOverweightUpgrade
Jun 05, 2023SVB LeerinkMarket PerformUnderperformDowngrade
May 23, 2023WedbushOutperformOutperformHold
Dec 14, 2022NeedhamBuyInitialise
Sep 06, 2022OppenheimerOutperformOutperformHold
Jun 13, 2022SVB LeerinkMarket PerformMarket PerformHold
Jun 01, 2022JefferiesBuyUpgrade
May 18, 2022Piper SandlerNeutralNeutralHold
Apr 26, 2022Zacks Investment ResearchHoldUpgrade

Blueprint Medicines's last stock rating was published by Citigroup on Nov 05, 2024. The company gave BPMC a "Buy" rating, the same as its previous rate.

Blueprint Medicines Financial Forecast

Blueprint Medicines Revenue Forecast

Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Revenue------------$56.57M$57.57M$63.29M$38.78M$65.98M$36.55M$62.73M$107.02M$24.19M$27.30M$21.58M$34.11M$745.12M$8.34M$6.17M$51.53M$9.14M$5.11M
Avg Forecast$287.19M$287.19M$287.19M$196.11M$181.91M$169.00M$155.96M$146.14M$127.56M$104.02M$80.89M$67.12M$50.66M$45.60M$41.85M$34.10M$43.51M$37.28M$40.09M$103.65M$42.50M$23.21M$17.06M$30.75M$627.42M$7.17M$5.42M$26.00M$2.00M$1.98M
High Forecast$307.67M$307.67M$307.67M$210.09M$194.88M$181.05M$167.37M$158.69M$127.93M$104.02M$80.89M$74.82M$58.30M$48.86M$44.83M$36.53M$43.51M$37.28M$40.09M$103.65M$42.50M$23.21M$17.06M$30.75M$627.42M$7.17M$5.42M$26.00M$2.00M$1.98M
Low Forecast$264.93M$264.93M$264.93M$180.91M$167.81M$155.90M$141.25M$141.35M$127.19M$104.02M$80.89M$61.16M$42.74M$42.07M$38.60M$31.46M$43.51M$37.28M$40.09M$103.65M$42.50M$23.21M$17.06M$30.75M$627.42M$7.17M$5.42M$26.00M$2.00M$1.98M
# Analysts454434813799101689127781388913596447
Surprise %------------1.12%1.26%1.51%1.14%1.52%0.98%1.56%1.03%0.57%1.18%1.26%1.11%1.19%1.16%1.14%1.98%4.58%2.58%

Blueprint Medicines's average Quarter revenue forecast for Dec 23 based on 10 analysts is $67.12M, with a low forecast of $61.16M, and a high forecast of $74.82M. BPMC's average Quarter revenue forecast represents a 18.66% increase compared to the company's last Quarter revenue of $56.57M (Sep 23).

Blueprint Medicines EBITDA Forecast

Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts454434813799101689127781388913596447
EBITDA------------$-128.98M$-127.98M$-123.22M$-149.80M$-122.66M$-156.17M$-104.18M$-314.39M$-115.45M$-106.66M$-98.11M$-85.42M$636.00M$-121.81M$-109.38M$-68.41M$-91.66M$-97.17M
Avg Forecast$-207.41M$-207.41M$-207.41M$-141.63M$-131.38M$-122.05M$-112.63M$-105.55M$-92.13M$-75.13M$-149.79M$-48.48M$-36.59M$-32.94M$-136.18M$-178.03M$-31.42M$-26.93M$-107.65M$-74.86M$-30.69M$-16.76M$-105.98M$-22.21M$-453.13M$-5.18M$-107.81M$-18.78M$-1.44M$-1.43M
High Forecast$-191.33M$-191.33M$-191.33M$-130.65M$-121.19M$-112.59M$-102.01M$-102.08M$-91.86M$-75.13M$-119.84M$-44.17M$-30.87M$-30.38M$-108.94M$-142.42M$-31.42M$-26.93M$-86.12M$-74.86M$-30.69M$-16.76M$-84.78M$-22.21M$-453.13M$-5.18M$-86.25M$-18.78M$-1.44M$-1.43M
Low Forecast$-222.20M$-222.20M$-222.20M$-151.73M$-140.74M$-130.76M$-120.88M$-114.61M$-92.40M$-75.13M$-179.75M$-54.04M$-42.10M$-35.28M$-163.41M$-213.63M$-31.42M$-26.93M$-129.18M$-74.86M$-30.69M$-16.76M$-127.17M$-22.21M$-453.13M$-5.18M$-129.37M$-18.78M$-1.44M$-1.43M
Surprise %------------3.53%3.89%0.90%0.84%3.90%5.80%0.97%4.20%3.76%6.36%0.93%3.85%-1.40%23.52%1.01%3.64%63.58%68.00%

13 analysts predict BPMC's average Quarter EBITDA for Dec 20 to be $-22.21M, with a high of $-22.21M and a low of $-22.21M. This is -103.49% lower than Blueprint Medicines's previous annual EBITDA (Sep 20) of $636.00M.

Blueprint Medicines Net Income Forecast

Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts454434813799101689127781388913596447
Net Income------------$-133.71M$-132.79M$-129.56M$-158.64M$-133.16M$-159.71M$-106.00M$-318.69M$-117.24M$-108.44M$-99.71M$-85.67M$633.98M$-123.47M$-110.95M$-66.33M$-94.28M$-99.68M
Avg Forecast$70.99M$70.35M$69.72M$-6.47M$-16.43M$-26.92M$-35.58M$-44.16M$-60.91M$-81.49M$-153.05M$-129.28M$-150.04M$-159.61M$-139.14M$-180.46M$-156.31M$-140.75M$-109.99M$-45.07M$-100.81M$-116.04M$-107.71M$-100.39M$431.49M$-134.33M$-109.35M$-106.52M$-136.09M$-120.01M
High Forecast$77.57M$76.87M$76.18M$-5.82M$-14.78M$-24.20M$-28.12M$126.18M$-54.78M$-73.28M$-122.44M$-116.60M$-134.85M$-143.52M$-111.31M$-144.37M$-156.31M$-140.75M$-87.99M$-45.07M$-100.81M$-116.04M$-86.17M$-100.39M$431.49M$-134.33M$-87.48M$-106.52M$-136.09M$-120.01M
Low Forecast$63.83M$63.26M$62.69M$-7.07M$-17.96M$-29.41M$-48.78M$-86.52M$-66.56M$-89.05M$-183.66M$-143.22M$-170.30M$-174.40M$-166.96M$-216.55M$-156.31M$-140.75M$-131.99M$-45.07M$-100.81M$-116.04M$-129.25M$-100.39M$431.49M$-134.33M$-131.23M$-106.52M$-136.09M$-120.01M
Surprise %------------0.89%0.83%0.93%0.88%0.85%1.13%0.96%7.07%1.16%0.93%0.93%0.85%1.47%0.92%1.01%0.62%0.69%0.83%

Blueprint Medicines's average Quarter net income forecast for Dec 20 is $-100.39M, with a range of $-100.39M to $-100.39M. BPMC's average Quarter net income forecast represents a -115.83% decrease compared to the company's last Quarter net income of $633.98M (Sep 20).

Blueprint Medicines SG&A Forecast

Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts454434813799101689127781388913596447
SG&A------------$70.74M$71.93M$70.95M$64.02M$57.61M$58.69M$57.06M$54.20M$49.81M$49.29M$42.00M$42.54M$37.38M$42.17M$35.66M$32.27M$25.65M$21.92M
Avg Forecast$291.74M$291.74M$291.74M$199.22M$184.79M$171.68M$158.43M$148.46M$129.59M$105.67M$82.18M$68.19M$51.46M$46.33M$42.51M$30.69M$44.20M$37.87M$40.73M$105.29M$43.17M$23.57M$17.33M$31.24M$637.37M$7.28M$5.50M$26.41M$2.03M$2.01M
High Forecast$312.55M$312.55M$312.55M$213.42M$197.97M$183.92M$170.02M$161.21M$129.96M$105.67M$82.18M$76.01M$59.22M$49.63M$45.54M$36.83M$44.20M$37.87M$40.73M$105.29M$43.17M$23.57M$17.33M$31.24M$637.37M$7.28M$5.50M$26.41M$2.03M$2.01M
Low Forecast$269.13M$269.13M$269.13M$183.77M$170.47M$158.37M$143.49M$143.59M$129.21M$105.67M$82.17M$62.13M$43.42M$42.74M$39.22M$24.55M$44.20M$37.87M$40.73M$105.29M$43.17M$23.57M$17.33M$31.24M$637.37M$7.28M$5.50M$26.41M$2.03M$2.01M
Surprise %------------1.37%1.55%1.67%2.09%1.30%1.55%1.40%0.51%1.15%2.09%2.42%1.36%0.06%5.79%6.48%1.22%12.65%10.91%

Blueprint Medicines's average Quarter SG&A projection for Dec 23 is $68.19M, based on 10 Wall Street analysts, with a range of $62.13M to $76.01M. The forecast indicates a -3.61% fall compared to BPMC last annual SG&A of $70.74M (Sep 23).

Blueprint Medicines EPS Forecast

Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
# Analysts454434813799101689127781388913596447
EPS------------$-2.20$-2.19$-2.15$-2.65$-2.23$-2.68$-1.79$-5.40$-2.00$-1.86$-1.72$-1.53$11.49$-2.28$-2.11$-1.35$-1.93$-2.04
Avg Forecast$1.12$1.11$1.10$-0.10$-0.26$-0.42$-0.56$-0.70$-0.96$-1.29$-1.67$-2.04$-2.37$-2.52$-2.67$-2.65$-2.49$-2.24$-1.91$-0.72$-1.60$-1.85$-1.89$-1.60$6.87$-2.14$-2.05$-1.69$-2.17$-1.91
High Forecast$1.22$1.21$1.20$-0.09$-0.23$-0.38$-0.44$1.99$-0.86$-1.16$-1.50$-1.84$-2.13$-2.26$-2.40$-2.39$-2.49$-2.24$-1.91$-0.72$-1.60$-1.85$-1.89$-1.60$6.87$-2.14$-2.05$-1.69$-2.17$-1.91
Low Forecast$1.01$1.00$0.99$-0.11$-0.28$-0.46$-0.77$-1.37$-1.05$-1.40$-1.82$-2.26$-2.69$-2.75$-2.92$-2.90$-2.49$-2.24$-1.91$-0.72$-1.60$-1.85$-1.89$-1.60$6.87$-2.14$-2.05$-1.69$-2.17$-1.91
Surprise %------------0.93%0.87%0.81%1.00%0.90%1.20%0.94%7.53%1.25%1.01%0.91%0.96%1.67%1.07%1.03%0.80%0.89%1.07%

According to 13 Wall Street analysts, Blueprint Medicines's projected average Quarter EPS for Dec 20 is $-1.60, with a low estimate of $-1.60 and a high estimate of $-1.60. This represents a -113.90% decrease compared to BPMC previous annual EPS of $11.49 (Sep 20).

Blueprint Medicines Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
INZYInozyme Pharma$2.94$16.00444.22%Buy
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
MREOMereo BioPharma Group$3.40$8.00135.29%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
PTCTPTC Therapeutics$47.02$48.002.08%Hold

BPMC Forecast FAQ

Is Blueprint Medicines a good buy?

Yes, according to 14 Wall Street analysts, Blueprint Medicines (BPMC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 64.29% of BPMC's total ratings.

What is BPMC's price target?

Blueprint Medicines (BPMC) average price target is $122.6 with a range of $88 to $155, implying a 36.01% from its last price of $90.14. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Blueprint Medicines stock go up soon?

According to Wall Street analysts' prediction for BPMC stock, the company can go up by 36.01% (from the last price of $90.14 to the average price target of $122.6), up by 71.95% based on the highest stock price target, and down by -2.37% based on the lowest stock price target.

Can Blueprint Medicines stock reach $140?

BPMC's highest twelve months analyst stock price target of $155 supports the claim that Blueprint Medicines can reach $140 in the near future.

What are Blueprint Medicines's analysts' financial forecasts?

Blueprint Medicines's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $458.62M (high $471.54M, low $453.45M), average EBITDA is $-423M (high $-389M, low $-462M), average net income is $-340M (high $-124M, low $-426M), average SG&A $465.89M (high $479.02M, low $460.64M), and average EPS is $-4.61 (high $-1.528, low $-5.641). BPMC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $702.97M (high $753.39M, low $645.86M), average EBITDA is $-508M (high $-466M, low $-544M), average net income is $-85.404M (high $-72.923M, low $-103M), average SG&A $714.12M (high $765.33M, low $656.1M), and average EPS is $-1.347 (high $-1.151, low $-1.629).

Did the BPMC's actual financial results beat the analysts' financial forecasts?

Based on Blueprint Medicines's last annual report (Dec 2023), the company's revenue was $249.38M, beating the average analysts forecast of $205.23M by 21.51%. Apple's EBITDA was $-486M, beating the average prediction of $-254M by 91.32%. The company's net income was $-507M, missing the average estimation of $-578M by -12.30%. Apple's SG&A was $295.14M, beating the average forecast of $208.49M by 41.56%. Lastly, the company's EPS was $-8.5, missing the average prediction of $-9.593 by -11.40%. In terms of the last quarterly report (Sep 2023), Blueprint Medicines's revenue was $56.57M, beating the average analysts' forecast of $50.66M by 11.66%. The company's EBITDA was $-129M, beating the average prediction of $-36.587M by 252.53%. Blueprint Medicines's net income was $-134M, missing the average estimation of $-150M by -10.88%. The company's SG&A was $70.74M, beating the average forecast of $51.46M by 37.46%. Lastly, the company's EPS was $-2.2, missing the average prediction of $-2.367 by -7.07%